Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,785

Document Document Title
WO/2019/054402A1
Provided is a tetrazolopyridine compound useful as an organic semiconductor material. A compound according to the present invention is characterized by being represented by any one of formulae (1)-(3). In formulae (1)-(3), Y1 and Y2, eac...  
WO/2019/050988A1
Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a phar...  
WO/2019/046551A1
Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.  
WO/2019/043451A1
A compound characterized by comprising at least one of each of a first divalent organic group represented by formula (1), and a second divalent organic group selected from formula (2a) and formula (2b), wherein the first divalent organic...  
WO/2019/043208A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  
WO/2019/042409A1
A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable sa...  
WO/2019/043214A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  
WO/2019/043217A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  
WO/2019/043417A1
The invention relates to a compound of formula (I) or formula (II) or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers or mixtures thereof; which are useful as medicaments, in particular as anti-proliferative agents ...  
WO/2019/038448A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices.According to the invention, the organic compound consists of - a first chemical moiety with a structure of formula I, and - two sec...  
WO/2019/038195A1
The present invention relates to novel condensed bicyclic heterocyclene derivatives of formula (I), wherein Aa, Ab, Ac, Ad and Q have the abovementioned meanings, agrochemical formulations comprising the compounds according to formula (I...  
WO/2019/034973A1
A compound having the structure: (I) or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification...  
WO/2019/029620A1
Provided is a compound of formula I with an ATX inhibitory activity and the application thereof in preparing drugs for treating ATX related diseases.  
WO/2019/032654A1
Disclosed herein are octahydropyrrolo[3,4-b]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositi...  
WO/2019/032863A1
The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as in...  
WO/2019/020041A1
Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or...  
WO/2019/023468A1
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.  
WO/2019/015689A1
Provided are a chiral 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I-A or I-B or a pharmaceutically acceptable salt, isomer or a mixture there...  
WO/2019/016324A1
The invention relates to an amphiphilic organic molecule for the self-assembly of active layers in electronic components, said molecule having at least one donor-acceptor system and chemical groups, wherein the donor-acceptor system incl...  
WO/2019/015593A1
Provided is a pyridopyrimidinone or pyridopyridone compound having a structure of the formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof. Such compounds can inhibit the activ...  
WO/2019/016071A1
The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations compris...  
WO/2019/014308A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/008011A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...  
WO/2019/002175A1
The invention relates to an organic molecule, in particular for use in optoelectronic components. According to the invention, the organic molecule contains - a first chemical unit having a structure of formula (I) and - two second chemic...  
WO/2019/001460A1
The invention relates to a polycyclic compound serving as IRAK4 inhibitor and uses thereof in preparing a drug treating IRAK4-associated diseases. More specifically, the invention relates to said compound represented by formula (I) and a...  
WO/2018/234807A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)  
WO/2018/234345A1
Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/233684A1
The present invention relates to 7-site substituted pyrrole [2,1-f][1,2,4] triazine compounds or pharmaceutically acceptable salts thereof, and a preparation method therefor and uses thereof. This kind of compound shows good PI3K inhibit...  
WO/2018/220531A1
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a com...  
WO/2018/218696A1
Provided is a ligand compound ofα7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nico...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/218197A2
The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.  
WO/2018/218133A1
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure...  
WO/2018/211275A1
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor ...  
WO/2018/210298A1
The present invention relates to a heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new heteroaryl-pyrazole derivative as shown in formu...  
WO/2018/213211A1
The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present d...  
WO/2018/209667A1
Disclosed in the present invention are crystal forms of a polycyclic heterocyclic compound, preparation methods therefor, applications thereof and a composition thereof. The present invention provides polymorphic forms of a compound of F...  
WO/2018/206820A1
The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the ph...  
WO/2018/209074A1
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds provided herein (e.g., compounds of Table 1), can be used to treat disorders associated with disorders neuronal excitability, KCNQ channel subunits or mutations in the...  
WO/2018/203194A1
Compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating bacterial infection is disclosed.  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/204416A1
The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.  
WO/2018/198077A3
The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined her...  
WO/2018/198077A2
The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined her...  
WO/2018/200425A1
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering ...  
WO/2018/200855A1
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, an...  
WO/2018/198844A1
Provided is an organic EL element which exhibits high efficiency and high operational stability, while having low driving voltage. An organic electroluminescent element which has a light emitting layer between a positive electrode and a ...  
WO/2018/195321A1
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2018/192944A1
A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted...  
WO/2018/195243A1
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formulae (I) and (II). The invention also provides conjugates of the benzodiazepine comp...  

Matches 1 - 50 out of 9,785